Clinical trial
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
NCT06063850
Study timeline
Study start (actual)2024-06-12Date precision: day
Registry last updated2026-08-24
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Mesial Temporal Lobe Epilepsyunresolved
Interventions
AAV9-hSyn1-miGRIK2GENETIC
Sponsors & collaborators
UniQure Biopharma B.V.lead sponsor
Mapped research locations
BostonMassachusetts, United States1PhiladelphiaPennsylvania, United States1BaltimoreMaryland, United States1ClevelandOhio, United States1PittsburghPennsylvania, United States1BirminghamAlabama, United States1ColumbusOhio, United States1PhoenixArizona, United States1JacksonvilleFlorida, United States1AustinTexas, United States1BethesdaMaryland, United States1MilwaukeeWisconsin, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06063850 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.